Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

ternal development products. These products, and our valued employees who have supported them, have contributed to the company's revenue and cash flow growth in recent years," said Mark McDade, PDL's chief executive officer. "We believe we have created significant value in these important products and the supporting operations, and we're now looking for the right buyer that can build upon this value that has been created by PDL, while we move forward with implementation of our new strategic direction."

About PDL

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. For more information, please visit http://www.pdl.com.

Forward-looking Statements

This press release contains forward-looking statements, including regarding PDL's plans to change its strategic focus; sell its commercial assets, including its Cardene, Retavase and Busulfex product rights, and ularitide development-stage cardiovascular product; an anticipated workforce reduction; and the advancement of PDL's clinical antibody pipeline, each of which involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: additional developments or decisions could cause PDL to alter its strategic focus; PDL may not be able to negotiate the sale of its commercial assets on terms acceptable to it; the consummation of any sale of commercial assets, even if on acceptable terms, could be adversely impacted or prevented by failure to satisfy closing conditions or regulatory delays; and PDL's success in advancing its pipeline could be adversely affected by failure or delay of clinical development programs, including because of delays in
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced the ... Strategic Business Report" report to their offering. ... Supplies in US$ Thousands by the following Product Segments: Media, Sera, ... the US, Canada , Japan ... and Latin America . Annual estimates and forecasts ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... Oct. 2 The Matan Companies has teamed up ... for the development of the National Cancer Institute,s 330,000 ... Research Park in Frederick, Maryland. The state-of-the art ... construction immediately and is slated for delivery in mid ...
... Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., ... Officer. This position will be formally held by Dr. Fung ... Chapter 11 of the U.S. Bankruptcy Code or earlier, if ... interim, Dr. Fung will work as an independent consultant. ...
... J.D. , has opened Stipkala LLC,s new office in Cincinnati, ... Stipkala LLC is an intellectual property law firm with locations ... Guttman has more than nine years of patent law experience, ... entering patent law, Dr. Guttman acquired over ten years of ...
Cached Biology Technology:Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 2Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 3Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 4Vermillion Announces Return of Eric Fung, M.D., Ph.D. 2Vermillion Announces Return of Eric Fung, M.D., Ph.D. 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... HOUSTON -- ( Aug. 19, 2014 ) -- Scientists ... how to pick up and transfer single cells using ... tweaked slightly. They describe this engineering feat and preliminary ... Journal of the American Chemical Society . , "Studying ... frontier in current biomedical research," said nanomedicine department. faculty ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2
... marine vibrio bacteria discovered in the last five years, can ... in Edinburgh. , The most common disease of vibrios is ... fatality in humans. Recent interest in this genus of bacteria ... from seawater and marine animals. , New species have been ...
... professor of molecular and human genetics at Baylor College of ... in bacteria stressed by starvation, sometimes resulting in a rare ... a report in the current issue of the journal Molecular ... happens but also show that this only occurs at a ...
... Scientists from the Public Health Agency of Canada - ... of Infectious Diseases - have developed vaccines against the ... be effective in non-human primates. , In a study ... Heinz Feldmann and Dr. Steven Jones of PHAC's National ...
Cached Biology News:Stressed cells spark DNA repair missteps and speed evolution 2Researchers report breakthrough against world’s deadliest viruses 2
... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse sTNF RII/TNFRSF1B...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: